NCT00202007已完成2 期
A Multi-Center, Randomized, Double-Blind Study, Comparing With Risperidone, to Evaluate the Efficacy and Safety of Aripiprazole in the Treatment of Patients With Schizophrenia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 240
- 试验地点
- 6
- 主要终点
- Deduction rate of PANSS total
研究概览
简要总结
This study design is subject to relevant SFDA regulations about clinical trials. Patients will be screened for inclusion into the study at the initial visit(240 patients to be recruited) and then undergo a minimum of 3-7 day's placebo washout period(placebo wash out is to eliminate the effect of prior antipsychotic medication with tablets without any active ingredients)(patients without prior antipsychotic medication are exempt from the washout phase). After screening and washout period, eligible patients will be randomly assigned to the two treatment group, Aripiprazole or Risperidone, for 6 week's treatment. Patients will be hospitalized for the entire duration of the study. Patients' condition will be assessed weekly.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion criteria for screening
- •Schizophrenia or Acute schizophrenia-like psychotic disorder(ICD 10)
- •PANSS total of no less than 60
- •Age: 18-65; male or female
- •Informed consent from the legal guardians of the patients Inclusion criteria after washout
- •1.PANSS total of no less than 60 2.3-7days washout with placebo is required after discontinuation of other oral antipsychotics; No washout is needed for patients who had never taken any antipsychotics before; In cases that patients's condition is deemed clinically deteriorating and immediate treatment is needed, patients with less than 3 days' placebo washout could be randomized after notifying the sponsor 3.No serious function impairment in heart, liver or kidney.
排除标准
- •For screening
- •Tendency or history of suicide
- •Patients with extreme agitation, violent attacking behavior towards people and those who can hardly comply with treatment
- •Diagnosis of other mental diseases besides Schizophrenia
- •Diabetes or other serious unstable diseases or the following neurological diseases, migraine, epilepsy, Parkinson's disease, Alzheimer's disease, multiple sclerosis, stroke and TIA etc
- •Patients who take Fluoxetine in the past 1-month before screening
- •Patients who had participated any other clinical trial in the past 1-month before screening
- •History of alcohol or drug abuse or dependence
- •Pregnancy or breast-feeding
- •Patients who have had gastrointestinal operations that could affect drug absorption.
- •Allergy to Risperidone or Aripiprazole or hypersensitiveness to any drug
- •Patients who discontinued long-acting antipsychotics less than one treatment cycle before screening
- •Refractory schizophrenia patients who did not respond to treatments of two different type antipsychotics with adequate dose and course, or patients who did not respond to Clozapine
- •Patients who had Electroconvulsive Therapy (ECT) in the past 6 months After washout
- •Diagnosis of other mental diseases besides schizophrenia during the washout period
- •Significant abnormal ECG or laboratory examination results (ALT,AST>1.5 times of higher limit of normal range), not suitable to be enrolled based on the investigator's discretion.
结局指标
主要结局
Deduction rate of PANSS total
次要结局
- PANSS positive
- PANSS negative
- CGI
- CGI improvement
研究者
研究点 (6)
Loading locations...
相似试验
已完成
3 期
A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic AnginaVasospastic AnginaNCT02087007Korea Otsuka Pharmaceutical Co., Ltd.100
终止
3 期
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT01111565Otsuka Pharmaceutical Development & Commercialization, Inc.137
终止
3 期
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT01111539Otsuka Pharmaceutical Development & Commercialization, Inc.211
终止
3 期
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)Major Depressive Disorder (MDD)NCT01111552Otsuka Pharmaceutical Development & Commercialization, Inc.237
Unknown
不适用
Alpha-Stim AID and Major Depressive DisorderDepressive Disorder, MajorNCT04963907Electromedical Products International, Inc.230